Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: BILR 355 BS; Drug: Combivir®; Drug: Ritonavir

• Registration Number: NCT02256774
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to determine the effect of BILR 355/r on Combivir® pharmacokinetics and the effect of Combivir® on BILR 355 BS pharmacokinetics.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Primary Completion: 2005-05
• Status Verified: 2014-10
• Study First Submitted: 2014-10-02
• Study First Submitted QC: 2014-10-02
• Last Update Submitted: 2014-10-02
• Study First Posted: 2014-10-06
• Last Update Posted: 2014-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

1. Males or females who meet the inclusion/exclusion criteria, females are not pregnant or nursing, and agree to use a double-barrier method of birth control (condoms or diaphragm plus spermicide) throughout the trial (alone or in addition to other methods of birth control such as oral contraceptives)
2. Age ≥18 and <60 years
3. Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
4. Ability to give signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local regulations

Exclusion Criteria

1. Current (symptomatic within the last 30 days) and medically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
2. Surgery of gastrointestinal tract (except appendectomy)
3. Currently active (symptomatic within the last 30 days) diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
4. History of relevant orthostatic hypotension, fainting spells or blackouts
5. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
6. Intake of drugs with a long half-life (>24 hours) within one month prior to administration of study drug or during the trial (review with clinical monitor if questionable)
7. Use of drugs within 10 days prior to administration or during the trial, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation (review with clinical monitor if questionable)
8. Participation in another trial with an investigational drug within one month prior to administration or during the trial
9. Current smoker
10. Alcohol (more than 60 g/day) or drug abuse (positive urine test for illicit prescription or non-prescription drugs or drugs of abuse).
11. Recent blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
12. Excessive physical activities (within 1 week prior to study drug administration or during the trial)
13. Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator
14. Inability to comply with dietary regimen required by the protocol
15. Chronic or relevant acute infections
16. Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B surface antigen, or hepatitis C antibody positive)
17. HIV-1 infected as defined by a positive HIV ELISA test

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Combivir® plus BILR 355/Ritonavir	Combivir®	-
BILR 355/Ritonavir	BILR 355 BS	-
Combivir® plus BILR 355/Ritonavir	BILR 355 BS	-
BILR 355/Ritonavir	Ritonavir	-
Combivir® plus BILR 355/Ritonavir	Ritonavir	-

Primary Outcome Measures

Name	Time	Method
Area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state (AUC0-12h,ss)	up to day 18
Maximum measured concentration of the analyte in plasma at steady state over a dosing interval τ (Cmax,ss)	up to day 18

Secondary Outcome Measures

Name	Time	Method
Apparent volume of distribution during the terminal phase λz at steady state following an extravascular dose (Vz/Fss)	up to day 18
Number of subjects with clinically significant findings in vital signs	up to 49 days
Apparent clearance of the analyte in plasma following extravascular administration at steady state (CL/F,ss)	up to day 18
Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)	up to day 18
Number of subjects with adverse events	up to 49 days
Terminal half-life of the analyte in plasma at steady state (t1/2,ss)	up to day 18
Measured concentration of the analyte in plasma 12 hours post last dose at steady state (Cp12h, ss)	up to day 18
Number of subjects with abnormal laboratory parameters	up to 49 days